The S&P 500 Index stocks saw their aggregate trailing 12-month revenue per share grow by approximately 4% on average every year over the past five years. The share price of the benchmark for the U.S. stock market ($3,400.97 as of Monday) has gained nearly 65% over the past five years through Oct. 26.
Thus, investors may want to consider the following stocks, as they have outperformed the S&P 500 index in terms of superior five-year revenue per share growth rates.
Visa Inc
The first company that makes the cut is Visa Inc (V, Financial).
The San Francisco-based global provider of payment services saw its revenue per share increase by 15.5% on average every year over the past five years.
The share price is up 142.6% over the past five years to close at $193.07 on Monday, for a market capitalization of $422.23 billion and a 52-week range of $133.93 to $217.35 per share.
GuruFocus assigned the company a financial strength rating of 7 out of 10 and a profitability rating of 9 out of 10.
Wall Street sell-side analysts recommend a buy rating for this stock and have established an average target price of $227.53 per share.
NVIDIA Corp
The second company that qualifies is NVIDIA Corp (NVDA, Financial), a Santa Clara, California-based producer of graphics processing units and system on a chip units for the consumer electronics, computer hardware, semiconductors and video game industries.
The company saw its revenue per share increase by 20.1% on average every year over the past five years.
The share price rose more than 15-fold over the past five years to close at $525.65 per share on Monday, which determined a market capitalization of $326.92 billion and a 52-week range of $176.50 to $589.07.
GuruFocus assigned the company a financial strength rating of 7 out of 10 and a profitability rating of 10 out of 10.
Wall Street sell-side analysts recommend an overweight recommendation rating for this stock and have produced an average target price of $566.90 per share.
Abbott Laboratories
The third company that holds the criteria is Abbott Laboratories (ABT, Financial), a U.S. medical devices giant.
The company saw its revenue per share increase by 6.9% on average every year over the past five years.
Following this, the stock has increased 144% over the past five years to hit $109 per share at close on Monday, for a market capitalization of $193.18 billion and a 52-week range of $61.61 to $114.20.
GuruFocus assigned the company a financial strength rating of 5 out of 10 and a profitability rating of 7 out of 10.
Wall Street sell-side analysts recommend an overweight rating for this stock and have set an average target price of $119.56 per share.
Disclosure: I have no positions in any securities mentioned in this article.
Read more here:
- A Trio of High Dividend Yield Stock Picks
- 3 Japanese Stocks With Low Price-Book Ratios
- 3 High Earnings Return Stocks
Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.
